Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 11.12% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the third quarter of 2017. Our consensus called for EPS of $1.13, and the company reported EPS of $1.44.
Revenue: Revenues, however, missed expectations. Alexion posted revenues of $859 million, compared to our consensus estimate of $867 million.
Key Stats: Solirus sales increased 4% in the quarter to $756 million.
2017 Guidance: The company increased its revenue and earnings guidance for 2017. The company expects adjusted earnings per share to be in the range of $5.50 to $5.65 up from its previous expectation of $5.40 to $5.55. It projects revenues to be in the range of $3.48 to $3.53 billion up from its prior expectation of $3.45 to $3.53 billion. The Zacks Consensus Estimate for earnings for 2017 was $5.60 per share while for sales it was $3.52 billion.
Share Price Impact: Shares rose 1.13% in pre-market trading.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Image: Bigstock
Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 11.12% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the third quarter of 2017. Our consensus called for EPS of $1.13, and the company reported EPS of $1.44.
Revenue: Revenues, however, missed expectations. Alexion posted revenues of $859 million, compared to our consensus estimate of $867 million.
Key Stats: Solirus sales increased 4% in the quarter to $756 million.
2017 Guidance: The company increased its revenue and earnings guidance for 2017. The company expects adjusted earnings per share to be in the range of $5.50 to $5.65 up from its previous expectation of $5.40 to $5.55. It projects revenues to be in the range of $3.48 to $3.53 billion up from its prior expectation of $3.45 to $3.53 billion. The Zacks Consensus Estimate for earnings for 2017 was $5.60 per share while for sales it was $3.52 billion.
Share Price Impact: Shares rose 1.13% in pre-market trading.
Alexion Pharmaceuticals, Inc. Price
Alexion Pharmaceuticals, Inc. Price | Alexion Pharmaceuticals, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>